Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 mutation
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
Oncomine™ Dx Target Test (10)
Lung Cancer 8-Gene Kit
Oncomine™ Dx Target Test (10)
Lung Cancer 8-Gene Kit
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
afatinib
Resistant: A2 - Guideline
afatinib
Resistant
:
A2
afatinib
Resistant: A2 - Guideline
afatinib
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab
Resistant: A2 - Guideline
trastuzumab
Resistant
:
A2
trastuzumab
Resistant: A2 - Guideline
trastuzumab
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
ado-trastuzumab emtansine
Sensitive: A2 - Guideline
ado-trastuzumab emtansine
Sensitive
:
A2
ado-trastuzumab emtansine
Sensitive: A2 - Guideline
ado-trastuzumab emtansine
Sensitive
:
A2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
HER-2 mutation
Colorectal Cancer
HER-2 mutation
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Hormone Receptor Positive Breast Cancer
HER-2 mutation
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
trastuzumab + neratinib
Sensitive
:
C2
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
trastuzumab + neratinib
Sensitive
:
C2
HER-2 mutation
Gastric Cancer
HER-2 mutation
Gastric Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Lung Cancer
HER-2 mutation
Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Cervical Cancer
HER-2 mutation
Cervical Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab-cmkb
Sensitive: C2 – Inclusion Criteria
pembrolizumab + margetuximab-cmkb
Sensitive
:
C2
pembrolizumab + margetuximab-cmkb
Sensitive: C2 – Inclusion Criteria
pembrolizumab + margetuximab-cmkb
Sensitive
:
C2
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
HER-2 mutation
Lung Cancer
HER-2 mutation
Lung Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
BI 1810631
Sensitive: C2 – Inclusion Criteria
BI 1810631
Sensitive
:
C2
BI 1810631
Sensitive: C2 – Inclusion Criteria
BI 1810631
Sensitive
:
C2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
BI 1810631
Sensitive: C2 – Inclusion Criteria
BI 1810631
Sensitive
:
C2
BI 1810631
Sensitive: C2 – Inclusion Criteria
BI 1810631
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
pyrotinib + inetetamab
Sensitive: C2 – Inclusion Criteria
pyrotinib + inetetamab
Sensitive
:
C2
pyrotinib + inetetamab
Sensitive: C2 – Inclusion Criteria
pyrotinib + inetetamab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
SHR-A1811
Sensitive: C2 – Inclusion Criteria
SHR-A1811
Sensitive
:
C2
SHR-A1811
Sensitive: C2 – Inclusion Criteria
SHR-A1811
Sensitive
:
C2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Lung Cancer
HER-2 mutation
Lung Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
afatinib
Sensitive
:
C2
afatinib
Sensitive: C2 – Inclusion Criteria
afatinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
neratinib + temsirolimus
Sensitive: C3 – Early Trials
neratinib + temsirolimus
Sensitive
:
C3
neratinib + temsirolimus
Sensitive: C3 – Early Trials
neratinib + temsirolimus
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
neratinib
Sensitive: C3 – Early Trials
neratinib
Sensitive
:
C3
neratinib
Sensitive: C3 – Early Trials
neratinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login